EUVIMEDEUVIMED entdecken
Open Access

Combination of a TGF ‐β ligand trap ( RAP‐GRL ) and TMPRSS6 ‐ASO is superior for correcting β‐thalassemia

Amaliris Guerra iD, Nolan Hamilton, Ariel Rivera, Perry Demsko, Shuling Guo, Stefano Rivella

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Amaliris Guerra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Pediatrics, The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: beta-Thalassemia, Serine Endopeptidases, Membrane Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A recently approved drug that induces erythroid cell maturation (luspatercept) has been shown to improve anemia and reduce the need for blood transfusion in non‐transfusion‐dependent as well as transfusion‐dependent β‐thalassemia (BT) patients. Although these results were predominantly positive, not all the patients showed the expected increase in hemoglobin (Hb) levels or transfusion burden reduction. Additional studies indicated that administration of luspatercept in transfusion‐dependent BT was associated with increased erythropoietic markers, decreased hepcidin levels, and increased liver iron content. Altogether, these studies suggest that luspatercept may necessitate additional drugs for improved erythroid and iron management. As luspatercept does not appear to directly affect iron metabolism, we hypothesized that TMPRSS6 ‐ASO could improve iron parameters and iron overload when co‐administered with luspatercept. We used an agent analogous to murine luspatercept (RAP‐GRL) and another novel therapeutic, IONIS TMPRSS6‐LRx ( TMPRSS6‐ ASO), a hepcidin inducer, to treat non‐transfusion‐dependent BT‐intermedia mice. Our study shows that RAP‐GRL alone improved red blood cell (RBC) production, with no or limited effect on splenomegaly and iron parameters. In contrast, TMPRSS6‐ ASO improved RBC measurements, ameliorated splenomegaly, and improved iron overload most effectively. Our results provide pre‐clinical support for combining TMPRSS6‐ ASO and luspatercept in treating BT, as these drugs together show potential for simultaneously improving both erythroid and iron parameters in BT patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaSerine EndopeptidasesMembrane ProteinsMiceAnimalsRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsHumansTransforming Growth Factor betaIron OverloadHepcidinsIronFemaleMaleDrug Therapy, CombinationActivin Receptors, Type II

Substanzen

Serine EndopeptidasesluspaterceptMembrane ProteinsRecombinant Fusion ProteinsImmunoglobulin Fc Fragmentsmatriptase 2Transforming Growth Factor betaHepcidinsIronActivin Receptors, Type II

Autor:innen und Institutionen

  • Division of Hematology, Department of Pediatrics, The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Cell and Molecular Biology Affinity Group (CAMB), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
  • Raymond G. Perelman Center for Cellular and Molecular Therapeutics-CHOP, Philadelphia, Pennsylvania, USA.
  • Penn Center for Musculoskeletal Disorders, CHOP, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Amaliris Guerra

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Disease
  • Division of Diabetes, Endocrinology, and Metabolic Diseases
  • National Institutes of Health

Zitieren

APA

Guerra, A., Hamilton, N., Rivera, A., Demsko, P., Guo, S., & Rivella, S. (2024). Combination of a TGF ‐β ligand trap ( RAP‐GRL ) and TMPRSS6 ‐ASO is superior for correcting β‐thalassemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27332

Vancouver

Guerra A, Hamilton N, Rivera A, Demsko P, Guo S, Rivella S. Combination of a TGF ‐β ligand trap ( RAP‐GRL ) and TMPRSS6 ‐ASO is superior for correcting β‐thalassemia. American Journal of Hematology. 2024. doi:10.1002/ajh.27332

BibTeX
@article{Guerra2024,
  author = {Guerra, Amaliris and Hamilton, Nolan and Rivera, Ariel and Demsko, Perry and Guo, Shuling and Rivella, Stefano},
  title = {Combination of a TGF ‐β ligand trap ( RAP‐GRL ) and TMPRSS6 ‐ASO is superior for correcting β‐thalassemia},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27332}
}
Kostenlos starten →